GO:0090324 negative regulation of oxidative phosphorylation: Mitochondrial Bioenergetics Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090324 describes any process that decreases the rate or extent of oxidative phosphorylation (OXPHOS), the mitochondrial pathway that couples metabolite oxidation to ATP synthesis.
• Negative regulation of OXPHOS is achieved through transcriptional repression, post-translational modification, metabolite feedback, and signaling cascades that adjust electron transport chain (ETC) activity.
• Key negative regulators include ZHX2, NIT2, DYRK1A, and metabolic sensors such as AMPK, which restrain OXPHOS under specific physiological or pathological conditions.
• Dysregulated negative regulation of OXPHOS contributes to acute liver injury, hepatocellular carcinoma, gastric cancer, lung cancer, and T cell memory development.
• Experimental models for studying this process include CRISPR knockout, point-mutation, knock-in, and overexpression cell lines, combined with Seahorse respirometry, transcriptomics, and proteomics.
• EDITGENE provides custom CRISPR cell model generation and screening services to dissect negative regulation of oxidative phosphorylation in disease contexts.
Description
Oxidative phosphorylation (OXPHOS) is the mitochondrial process that generates most cellular ATP by coupling the oxidation of metabolites to the electron transport chain (ETC) and ATP synthase. The Gene Ontology term GO:0090324, negative regulation of oxidative phosphorylation, encompasses any process that decreases the frequency, rate, or extent of this ATP-generating pathway. This regulation is essential for matching energy supply to cellular demand and for preventing oxidative damage under stress conditions. Researchers study GO:0090324 to understand how cells adapt metabolism during development, immune responses, and cancer. Negative regulation of OXPHOS operates at multiple levels, including transcriptional control of ETC subunits, post-translational modifications of respiratory complexes, and feedback from metabolites such as NADH/NAD+ and ATP/ADP ratios. For example, ZHX2 acts as a transcriptional repressor of OXPHOS genes during acute liver injury, limiting mitochondrial activity. Similarly, NIT2 dampens OXPHOS in gastric cancer by interfering with BRD1 phase separation, enhancing chemosensitivity. These examples illustrate how negative regulation can be either protective or pathogenic depending on context. Understanding GO:0090324 is critical for developing therapies that target metabolic vulnerabilities in cancer and immune disorders. This article synthesizes current knowledge on the mechanisms, key genes, disease relevance, and research methods for studying negative regulation of oxidative phosphorylation, based on verified PubMed literature and QuickGO annotations.
negative regulation of oxidative phosphorylation At A Glance
| GO ID | GO:0090324 |
|---|---|
| GO term | negative regulation of oxidative phosphorylation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the rate of ADP phosphorylation to ATP coupled to metabolite oxidation via the respiratory chain |
| Regulatory level | Transcriptional, post-translational, and metabolic feedback |
| Key negative regulators | ZHX2, NIT2, DYRK1A, AMPK signaling |
| Disease relevance | Cancer, acute liver injury, immune regulation, T cell memory |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, Seahorse, RNA-seq, proteomics |
What Is GO:0090324?
GO:0090324, negative regulation of oxidative phosphorylation, is defined as any biological process that decreases the frequency, rate, or extent of the chemical reactions and pathways resulting in the phosphorylation of ADP to ATP that accompanies the oxidation of a metabolite through the operation of the respiratory chain. In simpler terms, it is the set of mechanisms that put the brakes on mitochondrial ATP production via OXPHOS.
Why Is negative regulation of oxidative phosphorylation Important in Cell Biology?
Negative regulation of oxidative phosphorylation is vital for cellular energy homeostasis, allowing cells to reduce mitochondrial ATP production when energy demand is low or when oxidative stress threatens damage. Dysregulation of this process is implicated in cancer metabolic reprogramming, where tumor cells often suppress OXPHOS to favor glycolysis or to survive under hypoxia. In immune cells, dampening OXPHOS controls inflammatory responses and memory T cell development. Thus, understanding GO:0090324 provides insights into fundamental biology and identifies therapeutic targets for metabolic diseases and cancer.
• Maintains energy balance by preventing excessive mitochondrial ATP production under low-demand conditions.
• Protects against oxidative stress by reducing electron transport chain activity when needed.
• Regulates immune cell function, including group 2 innate lymphoid cells and T cell memory.
• Contributes to cancer cell survival by suppressing OXPHOS in hepatocellular carcinoma and gastric cancer.
• Modulates chemosensitivity in gastric cancer through NIT2-mediated OXPHOS restraint.
• Influences ferroptosis defense in KRAS-driven lung cancer via lactate dehydrogenase B.
• Plays a role in acute liver injury through ZHX2-mediated transcriptional repression of OXPHOS genes.
• Provides targets for metabolic therapies aiming to shift cancer cell metabolism.
• Helps explain T cell memory development under glucose limitation via AMPK-SENP1-Sirt3 signaling.
• Offers a framework for studying mitochondrial diseases and metabolic disorders.
What Happens During negative regulation of oxidative phosphorylation?
Transcriptional repression of OXPHOS genes
In simple terms: Cells can turn down the production of mitochondrial energy machinery by blocking the reading of genes that make OXPHOS proteins.
Negative regulation of OXPHOS often begins with transcriptional repression of nuclear-encoded ETC and mitochondrial genes. ZHX2 has been identified as a negative regulator that represses OXPHOS gene expression during acute liver injury, limiting mitochondrial activity. Similarly, NIT2 dampens OXPHOS in gastric cancer by interfering with BRD1 phase separation, which affects chromatin accessibility at OXPHOS gene loci. These examples show that transcriptional control is a primary mechanism for reducing OXPHOS capacity.
Post-translational modification of respiratory complexes
In simple terms: Existing energy machinery can be quickly switched off by chemical tags added to the proteins that carry out OXPHOS.
Post-translational modifications, such as phosphorylation and acetylation, can directly inhibit ETC complex activity. For instance, DYRK1A-TGF-beta signaling axis determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma, suggesting that kinase signaling modifies respiratory components to reduce OXPHOS. Additionally, COX6c, a cytochrome c oxidase subunit, is involved in regulation of OXPHOS and diseases, highlighting the role of complex IV modifications. These modifications allow rapid, reversible suppression of OXPHOS without changing gene expression.
Metabolic feedback and signaling sensors
In simple terms: The cell senses its energy status and uses molecules like AMPK to slow down OXPHOS when energy is plentiful or when stress signals appear.
Metabolic sensors such as AMPK integrate energy status to regulate OXPHOS. Glucose limitation activates AMPK coupled with SENP1-Sirt3 signaling in mitochondria, which is required for T cell memory development and involves modulation of OXPHOS. Dopamine inhibits group 2 innate lymphoid cell-driven allergic lung inflammation by dampening mitochondrial activity, indicating that neurotransmitters can negatively regulate OXPHOS. These signaling pathways provide context-dependent control of OXPHOS.
Regulation through parallel activation
In simple terms: OXPHOS is controlled by multiple parallel signals that can be adjusted independently to fine-tune energy production.
The concept of parallel activation describes how OXPHOS is regulated through simultaneous changes in multiple steps, including substrate supply, electron transport, and ATP synthesis. Negative regulation can occur by reducing any of these parallel inputs, leading to decreased overall flux. This systems-level view helps explain how diverse signals converge to suppress OXPHOS.
Role of lactate dehydrogenase B in ferroptosis defense
In simple terms: In some cancers, a metabolic enzyme called LDHB helps cells avoid a type of cell death by influencing OXPHOS and related pathways.
Lactate dehydrogenase B (LDHB) noncanonically promotes ferroptosis defense in KRAS-driven lung cancer, a process that involves regulation of oxidative phosphorylation and redox balance. This indicates that negative regulation of OXPHOS can be intertwined with cell death pathways and metabolic reprogramming.
Key Genes Involved in GO:0090324 negative regulation of oxidative phosphorylation
The following genes and proteins are experimentally implicated in negative regulation of oxidative phosphorylation (GO:0090324) based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ZHX2 | Transcriptional repressor of OXPHOS genes during acute liver injury | Studied in liver injury models; KO/overexpression to assess OXPHOS gene expression |
| NIT2 | Dampens OXPHOS by interfering with BRD1 phase separation in gastric cancer | Target for enhancing chemosensitivity; KO and overexpression models |
| DYRK1A | Kinase signaling axis determining sensitivity to OXPHOS inhibition in HCC | Therapeutic target in hepatocellular carcinoma; point mutation and KO studies |
| COX6c | Cytochrome c oxidase subunit involved in OXPHOS regulation and diseases | Complex IV component; KO and knock-in to study ETC function |
| LDHB | Noncanonical promoter of ferroptosis defense in KRAS-driven lung cancer | Metabolic enzyme linking OXPHOS regulation to cell death; KO models |
| AMPK | Energy sensor activated by glucose limitation, coupled to SENP1-Sirt3 signaling | Regulates T cell memory; KO and pharmacological activation |
| SENP1 | DeSUMOylase in mitochondria, part of AMPK-SENP1-Sirt3 axis | Modulates OXPHOS for T cell memory; KO and overexpression |
| Sirt3 | Mitochondrial deacetylase in AMPK-SENP1-Sirt3 signaling | Regulates OXPHOS enzymes; KO and point mutation |
| BRD1 | Chromatin reader whose phase separation is targeted by NIT2 | Epigenetic regulator of OXPHOS genes; KO and knock-in |
| TGF-beta | Signaling pathway interacting with DYRK1A to modulate OXPHOS sensitivity | Cytokine signaling; overexpression and inhibition studies |
| Dopamine | Neurotransmitter that dampens mitochondrial activity in ILC2s | Immune regulation; receptor KO and agonist treatment |
| Group 2 innate lymphoid cells (ILC2s) | Immune cells whose mitochondrial activity is inhibited by dopamine | Allergic lung inflammation models; cell-specific KO |
| KRAS | Oncogene context for LDHB-mediated ferroptosis defense | Lung cancer models; point mutation and KO |
| Hepatocellular carcinoma cells | Cancer context for DYRK1A-TGF-beta axis | OXPHOS inhibition sensitivity; CRISPR screens |
| Gastric cancer cells | Cancer context for NIT2-BRD1 axis | Chemosensitivity studies; KO and overexpression |
| T cells | Immune cells where AMPK-SENP1-Sirt3 regulates memory development | Memory T cell differentiation; KO and metabolic assays |
| Acute liver injury models | Pathological context for ZHX2-mediated OXPHOS repression | In vivo and in vitro liver injury; KO and overexpression |
| Mitochondrial respiratory chain complexes | Direct targets of negative regulation | Biochemical and structural studies; subunit KO |
How Is negative regulation of oxidative phosphorylation Regulated?
Negative regulation of oxidative phosphorylation is itself controlled by upstream signaling pathways. The AMPK-SENP1-Sirt3 axis responds to glucose limitation to modulate mitochondrial metabolism for T cell memory development. DYRK1A-TGF-beta signaling determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma, indicating that growth factor pathways can adjust OXPHOS suppression. NIT2 regulation involves BRD1 phase separation, linking epigenetic machinery to OXPHOS gene expression. Additionally, dopamine signaling dampens mitochondrial activity in group 2 innate lymphoid cells, showing neuroimmune control of OXPHOS. These regulatory layers ensure context-specific tuning of OXPHOS.
negative regulation of oxidative phosphorylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ZHX2 | Acute liver injury | Liver-specific KO and overexpression in mice |
| NIT2 | Gastric cancer chemosensitivity | CRISPR KO and overexpression in gastric cancer cell lines |
| DYRK1A | Hepatocellular carcinoma | Point mutation and KO in HCC cell lines |
| LDHB | KRAS-driven lung cancer | KO and knock-in in lung cancer models |
| AMPK/SENP1/Sirt3 | T cell memory development | Conditional KO in T cells and metabolic assays |
Cancer metabolism and chemosensitivity
Negative regulation of OXPHOS is frequently hijacked in cancer. In hepatocellular carcinoma, the DYRK1A-TGF-beta signaling axis determines sensitivity to OXPHOS inhibition, suggesting that targeting this axis could improve therapy. In gastric cancer, NIT2 dampens OXPHOS by interfering with BRD1 phase separation, enhancing chemosensitivity. LDHB promotes ferroptosis defense in KRAS-driven lung cancer, linking OXPHOS regulation to cell death evasion. These findings highlight negative regulators of OXPHOS as potential therapeutic targets.
Acute liver injury
ZHX2 emerges as a negative regulator of mitochondrial OXPHOS during acute liver injury, where it represses OXPHOS gene expression to limit mitochondrial activity. This response may protect against oxidative damage but could also impair recovery. Understanding ZHX2 function provides insights into liver disease mechanisms and potential interventions.
Immune regulation and allergic inflammation
Dopamine inhibits group 2 innate lymphoid cell-driven allergic lung inflammation by dampening mitochondrial activity, including OXPHOS. This demonstrates that negative regulation of OXPHOS in immune cells can suppress inflammatory responses. Targeting this pathway might offer new strategies for allergic diseases.
T cell memory and metabolic adaptation
Glucose limitation activates AMPK coupled SENP1-Sirt3 signaling in mitochondria for T cell memory development, a process that involves negative regulation of OXPHOS. This metabolic checkpoint is critical for long-lived immunity and has implications for vaccine design and immunotherapy.
From negative regulation of oxidative phosphorylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X repress OXPHOS transcription? | CRISPR knockout of gene X in cell lines, followed by RNA-seq and Seahorse |
| Does a point mutation in gene Y alter OXPHOS inhibition? | CRISPR point mutation knock-in of the specific mutation |
| Does overexpression of gene Z reduce OXPHOS flux? | CRISPR knock-in of a tagged or constitutive overexpression cassette |
| What is the role of gene W in immune cell metabolism? | Conditional knockout in primary immune cells |
| Can a drug target negative regulators of OXPHOS? | CRISPR library screening combined with drug treatment |
| How does a signaling axis control OXPHOS? | Knock-in of reporters and phospho-mutants |
How to Study the negative regulation of oxidative phosphorylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Seahorse respirometry | Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) | Quantify OXPHOS flux in live cells after gene KO or drug treatment |
| RNA-seq | Transcript levels of OXPHOS genes and pathways | Identify transcriptional repression by ZHX2, NIT2 |
| Proteomics | Protein abundance and modifications of ETC complexes | Detect post-translational changes in respiratory subunits |
| CRISPR knockout screening | Gene essentiality and OXPHOS dependency | Discover negative regulators of OXPHOS in cancer cells |
| CRISPR point mutation knock-in | Effect of specific mutations on OXPHOS regulation | Model disease-associated mutations in DYRK1A or other genes |
| CRISPR overexpression knock-in | Gain-of-function effects on OXPHOS | Test if a gene suppresses OXPHOS when overexpressed |
| Metabolic flux analysis | ATP/ADP ratios, NADH/NAD+ levels | Assess energy status and feedback regulation |
| Immunofluorescence imaging | Mitochondrial morphology and protein localization | Visualize mitochondrial activity changes in immune cells |
Seahorse respirometry
Seahorse extracellular flux analysis measures oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) to assess OXPHOS and glycolysis in live cells. This method is widely used to quantify negative regulation of OXPHOS after genetic or pharmacological perturbations.
Transcriptomics and RNA-seq
RNA sequencing reveals changes in expression of nuclear-encoded OXPHOS genes and related pathways. It is used to identify transcriptional repression by factors such as ZHX2 and NIT2.
Proteomics and post-translational modification analysis
Mass spectrometry-based proteomics can quantify ETC complex subunits and their modifications, providing insights into post-translational regulation of OXPHOS.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens identify genes that negatively regulate OXPHOS. These screens are powerful for discovering novel regulators and drug targets.
How CRISPR Can Be Used to Study GO:0090324 negative regulation of oxidative phosphorylation
Knockout
CRISPR knockout of candidate negative regulators such as ZHX2 or NIT2 allows researchers to assess whether loss of function increases OXPHOS. This approach is used to validate transcriptional repressors and signaling components.
Point Mutation
CRISPR point mutation knock-in can introduce specific amino acid changes to study how post-translational modifications or disease-associated mutations affect negative regulation of OXPHOS. For example, mutations in DYRK1A can be modeled to understand sensitivity to OXPHOS inhibition.
Knock-in
CRISPR knock-in of tagged or reporter constructs enables tracking of endogenous protein localization and dynamics. This is useful for studying how regulators like AMPK or Sirt3 modulate OXPHOS in real time.
Overexpression
CRISPR-mediated overexpression via knock-in of a strong promoter can test gain-of-function effects. Overexpressing NIT2 or ZHX2 can confirm their role in dampening OXPHOS and altering chemosensitivity.
How EDITGENE Supports negative regulation of oxidative phosphorylation Research
Researchers studying negative regulation of oxidative phosphorylation-related genes often need to determine whether a candidate gene is causally involved in suppressing OXPHOS, and whether this regulation affects disease phenotypes. EDITGENE provides custom CRISPR cell models and screening services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of oxidative phosphorylation research.
Frequently Asked Questions About negative regulation of oxidative phosphorylation
What is negative regulation of oxidative phosphorylation (GO:0090324)?
It is any biological process that decreases the rate or extent of ATP synthesis via oxidative phosphorylation, often by repressing gene expression, modifying respiratory complexes, or altering metabolic signaling.
What genes are involved in negative regulation of oxidative phosphorylation?
Key genes include ZHX2, NIT2, DYRK1A, COX6c, LDHB, and components of the AMPK-SENP1-Sirt3 pathway.
How is oxidative phosphorylation negatively regulated in cancer?
In cancer, negative regulation can occur through transcriptional repression (e.g., NIT2 in gastric cancer) or signaling axes (e.g., DYRK1A-TGF-beta in hepatocellular carcinoma) to reduce OXPHOS and enhance survival or chemosensitivity.
What is the role of ZHX2 in oxidative phosphorylation?
ZHX2 acts as a transcriptional repressor of OXPHOS genes during acute liver injury, limiting mitochondrial activity.
How does NIT2 regulate oxidative phosphorylation?
NIT2 dampens OXPHOS by interfering with BRD1 phase separation, which affects chromatin regulation of OXPHOS genes in gastric cancer.
What methods are used to study negative regulation of oxidative phosphorylation?
Common methods include Seahorse respirometry, RNA-seq, proteomics, CRISPR knockout/knock-in, and metabolic flux analysis.
Can CRISPR be used to study negative regulation of oxidative phosphorylation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function in OXPHOS regulation.
What diseases are associated with dysregulated negative regulation of oxidative phosphorylation?
Diseases include acute liver injury, hepatocellular carcinoma, gastric cancer, KRAS-driven lung cancer, and immune disorders such as allergic lung inflammation.
How does AMPK signaling affect oxidative phosphorylation?
Glucose limitation activates AMPK coupled with SENP1-Sirt3 signaling in mitochondria, which modulates OXPHOS for T cell memory development.
What is the significance of COX6c in oxidative phosphorylation?
COX6c is a cytochrome c oxidase subunit involved in the regulation of OXPHOS and associated diseases, highlighting the role of complex IV.
Conclusion
Negative regulation of oxidative phosphorylation (GO:0090324) is a critical biological process that fine-tunes mitochondrial ATP production in response to cellular and environmental cues. Dysregulation of this process contributes to cancer, liver injury, and immune disorders, making it a rich area for therapeutic targeting. Advances in CRISPR technology and metabolic profiling now enable precise dissection of the genes and pathways that suppress OXPHOS. EDITGENE supports researchers with custom CRISPR cell models, library screening, and bioinformatics to accelerate discoveries in this field. By combining rigorous experimental models with multi-omics analysis, the mechanisms and disease relevance of negative regulation of oxidative phosphorylation can be elucidated.
References
- 1. Zhang Y et al.. 2023. ZHX2 emerges as a negative regulator of mitochondrial oxidative phosphorylation during acute liver injury.. Nat Commun 14(1):7527 PMID: 37980429
- 2. Wang C et al.. 2022. Novel role of COX6c in the regulation of oxidative phosphorylation and diseases.. Cell Death Discov 8(1):336 PMID: 35879322
- 3. Korzeniewski B. 2007. Regulation of oxidative phosphorylation through parallel activation.. Biophys Chem 129(2-3):93-110 PMID: 17566629
- 4. Cao Y et al.. 2023. Dopamine inhibits group 2 innate lymphoid cell-driven allergic lung inflammation by dampening mitochondrial activity.. Immunity 56(2):320-335.e9 PMID: 36693372
- 5. Cao Y et al.. 2025. DYRK1A-TGF-β signaling axis determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma.. Dev Cell 60(10):1483-1497.e7 PMID: 39798576
- 6. Wang Z et al.. 2024. NIT2 dampens BRD1 phase separation and restrains oxidative phosphorylation to enhance chemosensitivity in gastric cancer.. Sci Transl Med 16(774):eado8333 PMID: 39565874
- 7. Zhao L et al.. 2025. Lactate dehydrogenase B noncanonically promotes ferroptosis defense in KRAS-driven lung cancer.. Cell Death Differ 32(4):632-645 PMID: 39643712
- 8. He J et al.. 2021. Glucose limitation activates AMPK coupled SENP1-Sirt3 signalling in mitochondria for T cell memory development.. Nat Commun 12(1):4371 PMID: 34272364
